Pathwork Diagnostics Closes $30M Series C Round, Plans Investments in Sales Team, New Tests

Pathwork Diagnostics will use the proceeds from its latest round of financing to expand its sales and marketing activities and grow its menu of microarray-based tests.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.